CSF1R mutations in hereditary diffuse leukoencephalopathy with spheroids are loss of function

Citation for published version:
Pridans, C, Sauter, KA, Baer, K, Kissel, H & Hume, DA 2013, 'CSF1R mutations in hereditary diffuse leukoencephalopathy with spheroids are loss of function' Scientific Reports, vol 3, 3013. DOI: 10.1038/srep03013

Digital Object Identifier (DOI):
10.1038/srep03013

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Scientific Reports

Publisher Rights Statement:
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
CSF1R mutations in hereditary diffuse leukoencephalopathy with spheroids are loss of function

Clare Pridans¹*, Kristin A. Sauter¹*, Kristin Baer², Holger Kissel² & David A. Hume¹

¹The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian EH25 9RG, Scotland, UK, ²TaconicArtemis GmbH, 51063 Cologne, Germany.

Hereditary diffuse leukoencephalopathy with spheroids (HDLS) in humans is a rare autosomal dominant disease characterized by giant neuroaxonal swellings (spheroids) within the CNS white matter. Symptoms are variable and can include personality and behavioural changes. Patients with this disease have mutations in the protein kinase domain of the colony-stimulating factor 1 receptor (CSF1R) which is a tyrosine kinase receptor essential for microglia development. We investigated the effects of these mutations on Csf1r signalling using a factor dependent cell line. Corresponding mutant forms of murine Csf1r were expressed on the cell surface at normal levels, and bound CSF1, but were not able to sustain cell proliferation. Since Csf1r signalling requires receptor dimerization initiated by CSF1 binding, the data suggest a mechanism for phenotypic dominance of the mutant allele in HDLS.

Hereditary diffuse leukoencephalopathy with spheroids (HDLS) is an autosomal-dominant neurodegenerative condition with rather variable penetrance. A recent study identified mutations in the colony-stimulating factor 1 receptor (CSF1R) in multiple families with this disorder¹. Subsequently, CSF1R mutations were identified in a related disorder termed pigmented orthochromatic leukodystrophy². CSF1R signalling is required for the generation of the majority of mature macrophages³, including the microglia of the brain. CSF1-dependent microglial activation has been implicated in neural damage in a model of Charcot-Marie-Tooth disease⁴. The authors of the recent report suggest that the causal mutations in CSF1R result in a loss of function, although there was no evidence of altered CSF1R levels or phosphorylation state in blood or brain samples from HDLS patients. Conversely, in vitro analysis of transfected HeLa cells resulted in no detectable autophosphorylation in three HDLS CSF1R mutations. The authors suggest that the presence of wild type CSF1R in the heterozygous individuals as the cause of this discrepancy⁵. Heterozygous mutation of Csf1r in mice does not generate any phenotype, suggesting that haploinsufficiency is an unlikely explanation for the dominant inheritance in HDLS. An alternative suggestion was that in patients the products of the mutant allele might assemble into heterodimers with wild-type protein and have a dominant negative effect.

CSF1R is a type III receptor tyrosine kinase belonging to the platelet-derived growth factor (PDGF) receptor family whose members include PDGF-α and –β, the FMS-like tyrosine kinase 3 (FLT3) and the receptor for stem cell factor (c-KIT)⁶. These proteins have similar structures consisting of five immunoglobulin-like domains, a transmembrane domain, a juxtamembrane domain (JM) and a protein kinase domain divided in two by an insert domain (KID)⁷. Protein kinase domains are structurally conserved and as key regulators of most cellular pathways are frequently associated with disease and are often oncogenic⁸. Mutations in the kinase domains of PDGF-α and c-KIT result in increased receptor dimerization leading to gastrointestinal tumours and mastocytosis (reviewed in⁹) whilst FLT3 gain of function mutations are often found in acute myeloid leukemia¹⁰. Overexpression of CSF1R has been reported in a number of diseases including myeloid malignancies¹¹.

CSF1R, like many related tyrosine kinase receptors, exists in an autoinhibited state, stabilized by the JM domain¹²,¹³. Upon activation, the receptor dimerizes which results in autophosphorylation of a number of tyrosine residues in the intracellular domain and leads to recruitment of signalling molecules and ultimately internalization of the receptor. Yu et al. generated a CSF1R in which all 6 major tyrosines involved in signalling were replaced by phenylalanine. Restoration of Y807 (Y809 in human) produced a receptor that was able to support ligand independent proliferation in a factor dependent cell line¹⁴. Three recent HDLS case reports have found additional mutations; K793T¹⁶, A781V¹⁷ and R782H¹⁸. R782, in the catalytic loop, binds to Y809 in the autoinhibited CSF1R¹².
In this study, we chose four HDLS mutations and created expression plasmids introducing the corresponding mutation in murine Csf1r. All mutated residues are highly conserved and are located in the protein kinase (PTK) domain. In addition to these, we examined four other mutations. We included a mutation (K584E) in the conserved N terminal region of the PTK domain that has not previously been implicated in autoinhibition as well as a mutation in the activation loop (R814P). As a positive control, a kinase-defective receptor, K614R, with a mutation in the ATP-binding site was created. In addition, we created a double mutation within the catalytic site (V661I/T663A). The mutant proteins were expressed in IL-3-dependent Ba/F3 cells. Although these cells were originally referred to as pro-B cells, they express the myeloid-specific F4/80 and CD11b antigens and may therefore be an appropriate model system in which to investigate CSF1 signalling. We report that the mutations identified in HDLS as well as the K614R mutant were unable to sustain growth in CSF1. They were nevertheless expressed on the cell surface at the same level as the wild-type receptor and could be internalized in response to addition of CSF1. Csf1r signalling was intact in R814P, V661I/T663A and K584E whilst the latter two mutations displayed varying degrees of constitutive activity. We thus confirm that mutations of CSF1R in HDLS are loss of function and that the use of the Ba/F3 factor dependent cell line is an invaluable tool for assessing the effects of further Csf1r mutations in vitro.

Results
The protein kinase domain of human and mouse CSF1R is highly conserved. In order to examine the CSF1R mutations found in HDLS the equivalent murine mutations were produced. An overlay of the protein kinase domains of human and mouse CSF1R emphasizes the highly conserved nature of this protein (Figure 1). The kinase insert domain is not required for kinase activity and the highlighted mutations did not affect the structure of the protein kinase domain when modeled in YASARA (data not shown).

Csf1r mutants found in HDLS do not signal when expressed in Ba/F3 cells. Rademakers and colleaguesuggested that the CSF1R mutations are effectively gain of function, producing dominant negative repressors. To identify the nature of the mutations found in HDLS, equivalent murine Csf1r proteins were expressed in factor dependent Ba/F3 cells. Expression of the wild-type receptor generated cells that could survive and proliferate in CSF1 (Figure 2). FACS analysis confirmed surface expression of Csf1r in these wild-type receptor expressing cells (Figure 3A). Conversely, the four mutations reported by Rademakers et al. all produced cells that were unable to survive in CSF1 (Figure 2) and therefore the four HDLS mutations were cultured in IL-3. Because it was not possible to select for CSF1 dependence, not all cells were positive, but those that were demonstrated the same level of surface receptor as cells expressing wild-type receptor (Figure 3C).

Functional signaling depends on the mutation site within Csf1r. We examined four other Csf1r mutations: K584E, V661I/T663A, R814P and K614R, with the latter serving as a positive control for loss of kinase activity. Like the HDLS mutants, the K614R mutant receptor could not survive in CSF1 alone in Ba/F3 cells (Figure 2), yet still expressed Csf1r on the surface (Figure 3B). To further validate the hypothesis that conserved amino acids within the catalytic site are important for autoinhibition, we produced a double mutation within the active site (V661I/T663A) that was not predicted to impact kinase activity. This double mutant demonstrated a small but statistically significant amount of constitutive activity in promoting survival and proliferation of Ba/F3 cells in the absence of growth factors (Figure 2). K584E was constitutively active in Ba/F3 cells (Figure 2) and expressed Csf1r on the surface (Figure 3B) whilst Ba/F3 cells expressing the activation loop mutation (R814P) remained CSF1-dependent (Figure 2).

HDLS mutant Csf1r can bind CSF1, dimerize, and internalize. Upon binding of its ligand, (Csf1 or IL-34) the Csf1 receptor dimerizes and following autophosphorylation of intracellular tyrosine residues the receptor is internalized and eventually degraded. We have shown that the mutations in HDLS are unable to signal via Csf1r in the presence of CSF1 yet still express Csf1r on the surface. To confirm that loss of receptor kinase activity does not necessarily affect receptor downregulation we co-treated the factor dependent mutants with CSF1. In each case, addition of CSF1 down-regulated surface Csf1r (Figure 3C).

Discussion
Csf1r regulates the proliferation, differentiation and survival of cells of the mononuclear phagocyte lineage, which include the microglia in the brain. In this study we chose four CSF1R mutations identified in HDLS as well as a kinase defective mutation (K614R), a highly conserved lysine mutation (K584E), an activation loop mutation (R814P) and a double mutation (V661I/T663A) within the catalytic site of the Csf1r protein kinase domain and created the equivalent murine mutations.

The IL3-dependent Ba/F3 cell line was used to test the biological activity of mutant receptors. When wild type Csf1r is introduced into these cells, survival can be maintained in the presence of CSF1 alone. Autophosphorylation of Csf1r dimers in response to ligand binding initiates recruitment of and activation of downstream signaling molecules such as Src, Grb2, STAT proteins and PI3 kinase. Rademakers and colleagues found that Csf1 did not induce autophosphorylation of the 3 HDLS mutant CSF1R (E633K, M766T, and M875T) suggesting that they were kinase-dead, similar to K614A, which fails to exhibit tyrosine phosphorylation or kinase activity.

In keeping with this view, Ba/F3 expressing any of the HDLS mutations (E631K, M764T, I792T and M873T) were unable to survive in CSF1. Nevertheless, the mutant proteins were on the cell surface at similar levels to the wild type protein and were removed from the surface in response to CSF1 (Figure 3), consistent with previous evidence that receptor internalization does not require CSF1R kinase activity. These data demonstrate clearly that the
mutant receptors can form dimers and can bind CSF1. Hence, in heterozygous individuals, 75% of ligand-receptor complexes would be either mutant dimers, or wild-type mutant heterodimers. The consequence would be a 75% reduction in the formation of active CSF1-CSF1R dimers competent to signal upon addition of the ligand. The inactive dimers are nevertheless internalized and degraded, so there is no possibility to recycle the wild-type proteins into active complexes.

The intracellular domain of Csf1r is highly-conserved across species. Our data suggest that there are many other mutations that could

Figure 2 | Mutations in the intracellular domain of mCsf1r resulted in either loss of Csf1r signalling or promoted factor independent survival in Ba/F3 cells. Untransfected Ba/F3 (naïve) or Ba/F3 cells expressing wild-type or mutant mCsf1r were cultured alone or in either IL-3 or rhCSF1. The mean of 3 experiments ± SEM is shown. P values were <0.0001 and <0.002 when mutants were compared to wild-type mCsf1r growing in rhCSF1 (*) or in no growth factor (#) respectively.

Figure 3 | Csf1r expression in mCsf1r Ba/F3 cells. (A) Flow cytometry analysis of Csf1r expression on naive and wild-type mCsf1r Ba/F3 cells cultured in IL-3 or rhCSF1, respectively. (B) Left: Expression of Csf1r on naive cells cultured in IL-3 and on mutant cells capable of growth in rhCSF1; K584E, R814P and V659I/T661A. Right: Expression of Csf1r on naive and K614R mutant cells cultured in IL-3. (C) Expression of Csf1r on mCsf1r mutant cells cultured in IL-3 alone or both IL-3 and rhCSF1 compared to naive cells. All cells were gated on live cells as determined by negative staining for propidium iodide.
act in a dominant manner. In the autoinhibited CSF1R domain, E633 forms a salt bridge with the invariant amino acid K616\(^{12}\). Because E633K was identified in HDLS patients, we generated a mutant receptor in which K616 was mutated to arginine (K614R in mice) to further test the importance of this interaction. The K616R mutant is known to have reduced in vitro kinase activity\(^{14}\). Like the known HDLS mutants it was unable to survive in CSF1, highlighting the importance of the E633-K616 interaction in the autoinhibited CSF1R. Rademakers and colleagues\(^1\) also identified two splice site variants amongst the HDLS patients that generate in-frame deletions of Exon 13 or Exon 18. Exon 13 is very highly conserved across species, even in birds and fish. We tested K584E, a charge reversal of an invariant amino acid within the exon 13-encoded region. This mutation generated a constitutively-active receptor that could produce growth factor independent Ba/F3 cells. Previous studies used another factor dependent cell line to identify activating mutations in exon 18 of CSF1R. R802V was characterized, which is equivalent to a known activating mutant in c-kit, a receptor tyrosine kinase (RTK) that is a member of the same RTK subfamily as Csfr\(^{19}\). The R802V variant caused constitutive activation, and associated receptor internalization and degradation\(^2\). Mutation of Asp814 in the phosphotransferase domain of murine c-kit, has been shown to produce factor independent growth\(^{20}\). This amino acid is conserved in Csfr1. Unexpectedly, this mutation had no effect on function; the mutant receptor was able to sustain CSF1-dependent growth. We hypothesize that a hydrophobic amino acid substitution would have resulted in an activating mutation. Morley and colleagues found that substitution of human A802 with a polar residue could not transform FDC-P1 cells\(^{21}\). Conserved amino acids within the catalytic site of Csfr1 are considered to be important for autoinhibition. We produced a double mutation within the active site, V661I/T663A. Cells expressing the mutant grew in rhCSF1 but also displayed a subtle hypomorph and provide insight into neuroprotective roles of Csfr1 in the brain.

### Methods

**Cell culture.** Untransformed Ba/F3 (naive) or Ba/F3 cells expressing wild-type or mutant murine Csfr were maintained in RPMI 1640 containing 10% FCS, 25 U/ml penicillin, 25 μg/ml streptomycin and 2 mM Glutamax\(^{16}\) supplemented with either 5% conditioned media from x63-IL-3 cells\(^{22}\) or 10% (U/ml) 100 (ml) recombinant human CSF1 (rhCSF1, a gift from Chiron, USA).

**Plasmid construction and transfection.** The wild type murine Csfr and the mutations K614R and V659I/T661A were amplified from plasmids provided by Taconic using the following primers F: ACCATGGAGTTGGGGCCT and R: GGCCCAGCCTG. The receptor sequences were subcloned into pEF6/V5-His TOPO (Invitrogen). Murine mutations were prepared from the wild type Csfr pEF6/V5-His construct using Agilent’s QuikChange II XL Site-Directed Mutagenesis kit according to instructions. The mutagenic primers are listed in Table I with mutated nucleotides in bold and underlined. All clones were sequence verified.

For generation of cells expressing wild-type or mutant mCsfr1, 5 × 10\(^4\) Ba/F3 cells were electroporated (1 pulse, 300 V, 975 μF, GenePulser, Bio-Rad) with 10 μg pEF6 in 250 μl complete medium. Stable transfectants were selected in 10 μg/ml Blasticidin (Invitrogen).

**Cell viability assays.** 2 × 10\(^4\) cells/well of a 96-well plate were plated in complete medium either without growth factors, with x63-IL-3 conditioned media or 10\(^3\) U/ml (100 ng/ml) rhCSF1 and incubated at 37 °C, 5% CO\(_2\), for 72 h. MTT stock solution (5 mg/ml in PBS) was added directly to growth medium at a concentration of 0.5 mg/ml and the plate was incubated at 37 °C for 3 h. Solubilization of tetrazolium salt was achieved with a solution of 10% SDS/50% isopropanol/0.01 M HCl at 37 °C overnight. The plates were read at 570 nm with a reference wavelength of 650 nm.

**FACS analysis.** Cells capable of growth in rhCSF1 (wild-type Csfr, K584E, R814P and V659I/T661A) were starved of rhCSF1 24 hours prior to FACS analysis to allow for cell surface expression of the receptor. Cells unable to grow in rhCSF1 (K614R and the four HDLS mutants) were cultured in IL-3 prior to FACS analysis. Live cells were stained for Csfr expression with anti-Mouse CD115 (c-fms) PE (eBioscience) according to standard protocols and analysed on a FACS Calibur (BD). Dead cells were excluded with propidium iodoide staining (1 μg/ml). For analysis of cell surface Csfr1 downregulation, HDLS mutants were cultured in IL-3 and were also co-treated with rhCSF1 for 4 h prior to analysis.

**Protein visualization.** YASARA (http://www.yasara.org/) was used to predict the structure of the murine (aa540–917) and human (aa542–919) autoinhibited kinase domain based on the human crystallized structure (PDB ID code 2GOV) reported by Walter and colleagues\(^3\). Our models include the kinase insert domain which was omitted from 2GOV. Both proteins were aligned using MUSTANG\(^22\).

### Table I | Mutagenesis primers

<table>
<thead>
<tr>
<th>Human Mutation</th>
<th>Murine Mutation</th>
<th>Mutagenesis primers (S)</th>
</tr>
</thead>
</table>
| K586E          | K584E          | ACAACCTGCAATGTGTGAGAAGTCAGGAGCC |}

\(^{1}\)mutations from \(^{1}\).

neuronal homeostasis\(^2\). The generation of the HDLS mutations in the mouse germ line via ES cell mutagenesis may therefore generate subtle hypomorphs and provide insight into neuroprotective roles of Csfr1 in the brain.

---

8. Scheijen, B. & Griffin, J. D. Tyrosine kinase oncogenes in normal hematopoiesis
20. Gow, D. J.
14. Yu, W.
9. He, L. & Hristova, K. Physical-chemical principles underlying RTK activation,
(2012).
diffuse leukoencephalopathy with axonal spheroids caused by R782H mutation in
37. Konagurthu, A. S., Whisstock, J. C., Stuckey, P. J. & Lesk, A. M. MUSTANG: a
5. Groh, J. et al. Colony-stimulating factor-1 mediates macrophage-related neural
damage in a model for Charcot-Marie-Tooth disease type Ix. Brain 135, 88–104
(2012).
6. Rosnet, O. & Birnbaum, D. Hematopoietic receptors of class III receptor-type
(2000).
8. Scheijen, B. & Griffin, J. D. Tyrosine kinase oncogenes in normal hematopoiesis
9. He, L. & Hristova, K. Physical-chemical principles underlying RTK activation,
(2012).
11. El-Gamal, M. I., Anbar, H. S., Yoo, K. H. & Oh, C. H. FMS Kinase Inhibitors:
12. Walter, M. et al. The 2.7 A crystal structure of the autoinhibited human c-Fms
13. Schubert, C. et al. Crystal structure of the tyrosine kinase domain of colony-
stimulating factor-1 receptor (cFMS) in complex with two inhibitors. J Biol Chem
14. Yu, W. et al. CSF-1 receptor structure/function in MacCsf1r-/- macrophages:
regulation of proliferation, differentiation, and morphology. J Leukoc Biol 84,
15. Yu, W. et al. Macrophage proliferation is regulated through CSF-1 receptor
Involvement of the Corpus Callosum in a Patient with Hereditary Diffuse
Leukencephalopathy with Spheroids Carrying the de novo K793T Mutation of
diffuse leukencephalopathy with axonal spheroids caused by R782H mutation in
phosphorylation of the colony-stimulating factor 1 receptor can occur through an
intermolecular reaction that triggers receptor down modulation. Mol Cell Biol 10,
20. Gow, D. J. et al. Cloning and expression of porcine Colony Stimulating Factor-1
(CSF-1) and Colony Stimulating Factor-1 Receptor (CSF-1R) and analysis of the
species specificity of stimulation by CSF-1 and Interleukin 34. Cytokine (2012).
unique insert of cellular and viral fms protein tyrosine kinase domains is
dispensable for enzymatic and transforming activities. EMBO J 8, 2029–2037
(1989).
23. Uden, M., Morley, G. M. & Dibb, N. J. Evidence that downregulation of the M-CSF
receptor is not dependent upon receptor kinase activity. Oncogene 18, 3846–3851
(1999).
24. Palacios, R. & Steinmetz, M. II-3-dependent mouse clones that express B-220
surface antigen, contain Ig genes in germ-line configuration, and generate B
25. Rohde, C. M., Schrum, J. & Lee, A. W. A juxtamembrane tyrosine in the colony
stimulating factor-1 receptor regulates ligand-induced Src association, receptor
26. van der Geer, P. & Hunter, T. Mutation of Tyr697, a GRB2-binding site, and
Tyr721, a PI 3-kinase binding site, abrogates signal transduction by the murine
CSF-1 receptor expressed in Rat-2 fibroblasts. EMBO J 12, 5161–5172 (1993).
27. Novak, U. et al. Colony-stimulating factor 1-induced STAT1 and STAT3
activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2
28. Reediik, M. et al. Tyr721 regulates specific binding of the CSF-1 receptor kinase
intermediates PI 3’ kinase SH2 domains: a model for SH2-mediated receptor-target
29. Irvine, K. M. et al. A CSF-1 receptor kinase inhibitor targets effector functions
and inhibits pro-inflammatory cytokine production from murine macrophage
by c-fms activating loop mutations is attributable to constitutive receptor
32. Hashimoto, K. et al. Necessity of tyrosine 719 and phosphatidylinositol 3’-kinase-
mediated signal pathway in constitutive activation and oncogenic potential of c-
kit receptor tyrosine kinase with the Aq814V mutation. Blood 101, 1094–1102
(2003).
33. Emrick, M. A. et al. The gatekeeper residue controls autoactivation of ERK2 via a
pathway of intramolecular connectivity. Proc Natl Acad Sci U S A 103,
34. Yardi, S. et al. The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct
devvelopmental brain expression patterns and regulate neural progenitor cell
35. Luo, J. et al. Colony-stimulating factor 1 receptor (CSF1R) signaling in injured
36. Karasuyama, H. & Melchers, F. Establishment of mouse cell lines which
constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified
37. Konagurthu, A. S., Whisstock, J. C., Stuckey, P. J. & Lesk, A. M. MUSTANG: a

Author contributions
D.A.H. designed the project with contributions from C.P., K.A.S., K.B. and H.K. C.P., K.A.S.
and D.A.H. wrote the manuscript and all authors reviewed the manuscript. C.P. prepared
figures 1–2 and K.A.S prepared figure 3. C.P. and K.A.S. performed the experiments. K.B.
and D.A.H. wrote the manuscript and all authors reviewed the manuscript. C.P. prepared
funding and supervised the project.

Additional information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Pridans, C., Sauter, K.A., Baer, K., Kissel, H. & Hume, D.A. CSF1R
mutations in hereditary diffuse leukencephalopathy with spheroids are loss of function.

This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 Unported license. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0